Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways.
OBJECTIVE
Nicotine, the major component in cigarette smoke, can promote tumor growth and angiogenesis in various cancers, including lung cancer. Hypoxia-inducible factor-1alpha (HIF-1alpha) is overexpressed in human lung cancers, particularly in non-small cell lung cancers (NSCLC), and is closely associated with an advanced tumor grade, increased angiogenesis, and resistance to chemotherapy and radiotherapy. The purpose of this study was to investigate the effects of nicotine on the expression of HIF-1alpha and its downstream target gene, vascular endothelial growth factor (VEGF), in human lung cancer cells.


METHODS
Human NSCLC cell lines A549 and H157 were treated with nicotine and examined for expression of HIF-1alpha and VEGF using Western blot or ELISA. Loss of HIF-1alpha function using specific small interfering RNA was used to determine whether HIF-1alpha is directly involved in nicotine-induced tumor angiogenic activities, including VEGF expression, cancer cell migration, and invasion.


RESULTS
Nicotine increased HIF-1alpha and VEGF expression in NSCLC cells. Pharmacologically blocking nicotinic acetylcholine receptor-mediated signaling cascades, including the Ca2+/calmodulin, c-Src, protein kinase C, phosphatidylinositol 3-kinase, mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2, and the mammalian target of rapamycin pathways, significantly attenuated nicotine-induced up-regulation of HIF-1alpha protein. Functionally, nicotine potently stimulated in vitro tumor angiogenesis by promoting tumor cell migration and invasion. These proangiogenic and invasive effects were partially abrogated by treatment with small interfering RNA specific for HIF-1alpha.


CONCLUSIONS
These findings identify novel mechanisms by which nicotine promotes tumor angiogenesis and metastasis and provide further evidences that HIF-1alpha is a potential anticancer target in nicotine-associated lung cancer.
Zhang
Qunzhou
Q
Center for Craniofacial Molecular Biology, University of Southern California, School of Dentistry, CA 90033, USA.
Tang
Xudong
X
Zhang
Zuo-Feng
ZF
Velikina
Rita
R
Shi
Shihong
S
Le
Anh D
AD
D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D009361:Neoplasm Invasiveness; D009538:Nicotine / Q000494:pharmacology*; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D034741:RNA, Small Interfering / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis
C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D034741:RNA, Small Interfering; D011978:Receptors, Nicotinic; D042461:Vascular Endothelial Growth Factor A; D009538:Nicotine; D019869:Phosphatidylinositol 3-Kinases
Head Neck. 2001 Oct;23(10):860-70
11592233
FEBS Lett. 2002 Feb 13;512(1-3):157-62
11852072
Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G926-34
16051920
Cancer Res. 2001 May 15;61(10 ):3986-97
11358816
Br J Cancer. 2001 Sep 14;85(6):881-90
11556841
Cancer Res. 1997 Dec 1;57(23):5328-35
9393757
Mol Pharmacol. 2001 Dec;60(6):1201-9
11723227
Biochem J. 1997 Dec 1;328 ( Pt 2):499-503
9371707
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6332-7
16601104
Cardiovasc Res. 2005 Feb 15;65(3):564-73
15664382
Nat Med. 2001 Jul;7(7):833-9
11433349
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
12568441
J Biol Chem. 2005 Jun 10;280(23 ):22473-81
15802268
Cancer Res. 2005 Apr 15;65(8):3257-63
15833858
Carcinogenesis. 2005 Jul;26(7):1182-95
15790591
Int J Cancer. 2004 Aug 10;111(1):43-50
15185341
FASEB J. 2006 Oct;20(12):2093-101
17012261
J Natl Cancer Inst. 2005 Nov 16;97(22):1695-9
16288123
Proc Natl Acad Sci U S A. 1990 May;87(9):3294-8
2159143
Cancer Res. 2007 Jan 15;67(2):563-72
17234764
J Cell Biochem. 2006 Apr 15;97(6):1370-8
16365874
Cancer Res. 2006 Dec 1;66(23 ):11263-70
17145871
Blood. 1997 Nov 1;90(9):3322-31
9345014
Cancer Res. 2000 Mar 15;60(6):1541-5
10749120
Genes Dev. 2000 Feb 15;14 (4):391-6
10691731
J Clin Invest. 2003 Jan;111(1):81-90
12511591
Cell Growth Differ. 1994 Oct;5(10):1033-40
7848904
FASEB J. 2006 May;20(7):828-32
16675839
Mol Cell Biol. 1996 Sep;16(9):4604-13
8756616
Cancer Res. 2003 Mar 1;63(5):1138-43
12615733
Nat Rev Cancer. 2003 Oct;3(10):721-32
13130303
J Clin Invest. 2006 Aug;116(8):2208-2217
16862215
Biochem Biophys Res Commun. 2006 Apr 14;342(3):928-34
16598845
Respir Res. 2004 Dec 10;5:27
15588326
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5
10973499
Cancer Lett. 2004 Oct 28;214(2):157-64
15363541
Carcinogenesis. 1998 Apr;19(4):551-6
9600337
Carcinogenesis. 2004 Dec;25(12 ):2487-95
15319299
Trends Pharmacol Sci. 2004 Jun;25(6):317-24
15165747
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14184-9
9826675
J Biol Chem. 2002 Dec 13;277(50):48403-9
12379645
Cancer. 2000 Jun 1;88(11):2606-18
10861440
Nat Med. 2003 Jun;9(6):677-84
12778166
Am J Reprod Immunol. 2005 Mar;53(3):153-8
15727570
J Biol Chem. 2006 Feb 17;281(7):4457-66
16361262
Int J Cancer. 2004 Oct 10;111(6):849-57
15300796
Nat Med. 2004 Aug;10 (8):789-99
15286780
Mol Cancer Res. 2005 Nov;3(11):607-15
16317086
Pulm Pharmacol Ther. 2007;20(6):629-41
17015027